Completed PHASE1 INTERVENTIONAL NCT00038480

Safety and Effectiveness of Lopinavir/Ritonavir in HIV Infected Infants

A Phase I/II Study of Lopinavir/Ritonavir in HIV-1 Infected Infants Less Than 6 Months of Age

Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Updated 7 times since 2017 Last updated: Oct 28, 2021 Completion: Sep 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00038480, this PHASE1 trial focuses on HIV Infections and remains completed. Sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), it has been updated 7 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Dec 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Dec 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute of Allergy and Infectious Diseases (NIAID)

Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Baltimore, United States , Boston, United States , Chicago, United States , Jacksonville, United States , Memphis, United States , Minas Gerais, Brazil , Oakland, United States , Philadelphia, United States , San Francisco, United States and 6 more locations